Venofer denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for venofer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Venofer as Experimental

This denial reason is unusual for Venofer (iron sucrose injection) because the FDA approved iron sucrose for specific indications, and it has been in clinical use for decades. An "experimental" or "investigational" denial from Cigna in this context most commonly arises when Venofer is being used for an indication that falls outside Cigna's recognized list of covered uses — for example, a condition or patient population not explicitly addressed in their medical coverage policy — or when the claim coding does not clearly map to a covered indication.

## Why This Denial Is Appealable

Cigna's own clinical policy bulletins define what constitutes "established" versus "investigational" use; a use that is FDA-approved or supported by guidelines from the relevant specialty society (such as the applicable nephrology, gastroenterology, or hematology guidelines) typically does not qualify as experimental under those criteria. The appeal should demonstrate that the specific use is within the FDA-approved labeling or is otherwise recognized in published clinical practice guidelines from the applicable specialty organization.

## Federal Appeal Framework

• Internal appeal: Submit within the timeframe on the denial notice. Cigna must respond within 30 days for pre-service and 60 days for post-service standard appeals.
• Expedited review: If delay poses serious health risk, request expedited handling; Cigna must respond within 72 hours.
• External review (ACA §2719 / ERISA §503): After a final internal denial, you have approximately 4 months to request IRO external review. IRO decisions are binding on Cigna.

## Documentation to Gather

• FDA label extract: A copy of the current FDA-approved prescribing information for Venofer, with the relevant approved indication highlighted.
• Diagnosis documentation: Chart notes confirming the patient's diagnosis and how it maps to the approved indication.
• Guideline citation: A reference to the applicable clinical practice guideline from the relevant specialty society supporting this use for this diagnosis.
• Prescriber medical-necessity letter: A letter from the treating physician explaining the clinical basis for Venofer, citing the approved indication or guideline support, and explaining why the use is established rather than experimental.
• Clinical history: Documentation of the patient's disease course and why IV iron is required rather than an alternative approach.

## Criteria-Mapping Structure

Obtain Cigna's clinical policy bulletin for intravenous iron or for Venofer specifically. List each criterion Cigna uses to distinguish covered from experimental use. For each criterion, cite the specific FDA label language, guideline reference, or chart fact that demonstrates the use is established and covered.